New Zealand markets closed
  • NZX 50

    10,753.16
    -115.54 (-1.06%)
     
  • NZD/USD

    0.6177
    -0.0068 (-1.09%)
     
  • NZD/EUR

    0.5905
    -0.0048 (-0.80%)
     
  • ALL ORDS

    6,720.40
    -26.10 (-0.39%)
     
  • ASX 200

    6,539.90
    -28.20 (-0.43%)
     
  • OIL

    107.76
    +2.00 (+1.89%)
     
  • GOLD

    1,795.70
    -11.60 (-0.64%)
     
  • NASDAQ

    11,503.72
    -154.55 (-1.33%)
     
  • FTSE

    7,191.23
    +21.95 (+0.31%)
     
  • Dow Jones

    30,775.43
    -253.88 (-0.82%)
     
  • DAX

    12,831.06
    +47.29 (+0.37%)
     
  • Hang Seng

    21,859.79
    -137.10 (-0.62%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • NZD/JPY

    83.7650
    -0.9500 (-1.12%)
     

Quotient Limited Announces Opening of Office in Dubai, United Arab Emirates

·4-min read
Quotient Limited
Quotient Limited
  • Diversified global presence key to Company's go-to-market strategy

  • Strengthened geographical expansion with distributor strategy model to better support customers in the region

JERSEY, Channel Islands, May 17, 2022 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion plans to better support customers in the region.

“We are very pleased to announce the opening of our new office in Dubai, to reinforce growth opportunities in emerging markets,” said Manuel O. Méndez, Chief Executive Officer of Quotient. “This is the latest step in establishing a diversified global presence, which is vital to our commercial strategy and our goal to improve clinical practices and increase laboratory efficiencies across the globe.”

Quotient has received the CE Mark for its MosaiQ Extended Immunohematology Microarray, which substantially increases the range of tests that can be run on its MosaiQ consolidated testing platform. The Company is now commercializing the microarray for use in the EU and other CE Mark recognizing geographies. Quotient is also a leading global supplier of high-quality blood grouping reagents for use in the transfusion diagnostics market.

"We already have a strong base of distributors we work with in the Middle East and North Africa, thanks to our updated distributor strategy model" said Mohammad El Khoury, Chief Commercial Officer of Quotient. "Having received the CE Mark, we are now actively discussing commercial distribution offers with potential partners to expand our network across the EU, Middle East and Africa for the MosaiQ solution. The addition of the new Dubai office will be a major factor in driving our commercial achievements in the region."

About Quotient Limited

Building on over 30 years of experience in transfusion diagnostics, Quotient is a commercial-stage diagnostics company committed to delivering solutions that it believes reshape the way diagnostics are practiced. MosaiQ, Quotient’s proprietary multiplex microarray technology, offers the world’s first fully automated, consolidated testing platform, allowing for multiple tests across different modalities. MosaiQ is designed to be a game-changing solution, which Quotient believes will increase efficiencies, improve clinical practice, deliver significant workflow improvements, and create operational cost savings to laboratories around the world. Quotient's operations are based in Switzerland, Scotland, US and the UAE.

The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT: Investor Relations, ir@quotientbd.com; +41 22 545 52 26

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include statements regarding our expectations of continued growth, the development, regulatory approval, commercialization and impact of MosaiQ and other new products (including the potential for using the Company’s MosaiQ technology to infectious disease diagnostics), current estimates of fourth quarter and full year fiscal 2022 operating results and expectations regarding our future funding sources. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include delays or denials of regulatory approvals or clearances for products or applications; market acceptance of our products; the impact of competition; the impact of facility expansions and expanded product development, clinical, sales and marketing activities on operating expenses; delays or other unforeseen problems with respect to manufacturing, product development or field trial studies; adverse results in connection with any ongoing or future legal proceedings; continued or worsening adverse conditions in the general domestic and global economic markets, including as a result of the global COVID-19 pandemic; as well as the other risks set forth in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Quotient disclaims any obligation to update these forward-looking statements.

The Quotient logo, Quotient MosaiQ and MosaiQ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting